Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.
Sola is a rupture-resistant balloon catheter that uses laser energy to deliver 360-degree pressure with each pulse. It was designed to address limitations the company saw in current calcium-modification devices.
Care teams have a lot to consider when choosing the right treatment for patients with severe aortic stenosis. Two cardiologists and a veteran cardiothoracic surgeon are taking part in a new webinar focused on that very topic.
From new drug therapies and imaging technologies to updated prevention strategies, nearly every aspect of cardiovascular care is starting to embrace the value of coronary inflammation evaluations. Paul Ridker, MD, MPH, discussed the trend in a new interview.
The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications.
Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.
The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough.
This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.
The Cardiovascular Research Foundation (CRF) announced the 32 late-breaking studies being presented at the Transcatheter Cardiovascular Therapeutics 2022 annual meeting at in Boston, Sept. 16-19.
The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.
New research, published in JAMA Cardiology, challenges the common belief that AFib is more likely to develop among men than women. The key problem, it seems, is that prior research teams did not understand the significance of certain risk factors.
Philippe Genereux, MD, medical director of the Structural Heart Disease Program at Morristown Medical Center, discusses the use of transcatheter aortic valve replacement (TAVR) procedures in patients with severe, calcific aortic stenosis who are asymptomatic.
Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.
"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
